Cinromide in the treatment of absence seizures.

Cinromide (BW-122U) was evaluated in an open pilot study of absence seizures in three naive (previously untreated for absence seizures) patients (one male and two females, 7 to 8 years of age). In these naive patients, cinromide was found to be well tolerated but ineffective in reducing generalized spike-and-wave discharges on the telemetered EEG during the 1-week duration of the study.